CareDx Acquires Naveris for $260M to Expand Precision Medicine Capabilities
CareDx has agreed to acquire Naveris for up to $260 million, including an upfront payment of $160 million and potential additional payments based on revenue milestones. The acquisition is expected to close in Q3 2026 and will provide CareDx with a blood-based monitoring solution for viral-mediated cancers. The deal aligns with CareDx's strategic focus on precision oncology diagnostics.
Topics: acquisition CareDx diagnostics Naveris precision medicine